Cairncross JG, Ueki K, Zlatescu MC et al (1998) Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90:1473–1479

Article  CAS  PubMed  Google Scholar 

Ino Y, Betensky RA, Zlatescu MC et al (2001) Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. Clin Cancer Res: Off J Am Assoc Cancer Res 7:839–845

CAS  Google Scholar 

Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Ellison DW, Figarella-Branger D, Perry A, Reifenberger G, von Deimling A (2016) WHO classification of tumours of the central nervous system, 4th edn. International agency for research on cancer, Lyon

Google Scholar 

WHO Classification of Tumours Editorial Board (2021) Central nervous system tumours, 5th edn. International Agency for Research on Cancer, Lyon

Google Scholar 

Franceschi E, Tosoni A, Bartolini S et al (2020) Histopathological grading affects survival in patients with IDH-mutant grade II and grade III diffuse gliomas. Eur J Cancer 137:10–17

Article  CAS  PubMed  Google Scholar 

Cimino PJ, Zager M, McFerrin L et al (2017) Multidimensional scaling of diffuse gliomas: application to the 2016 World Health Organization classification system with prognostically relevant molecular subtype discovery. Acta Neuropathol Commun 5:39

Article  PubMed  PubMed Central  Google Scholar 

Lassman AB, Iwamoto FM, Cloughesy TF et al (2011) International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors. Neuro Oncol 13:649–659

Article  PubMed  PubMed Central  Google Scholar 

Lassman AB, Hoang-Xuan K, Polley MC et al (2022) Joint final report of EORTC 26951 and RTOG 9402: phase III trials with procarbazine, lomustine, and vincristine chemotherapy for anaplastic oligodendroglial tumors. J Clin Oncol: Off J Am Soc Clin Oncol 40:2539–2545

Article  CAS  Google Scholar 

Figarella-Branger D, Mokhtari K, Dehais C et al (2016) Mitotic index, microvascular proliferation, and necrosis define 3 pathological subgroups of prognostic relevance among 1p/19q co-deleted anaplastic oligodendrogliomas. Neuro Oncol 18:888–890

Article  PubMed  PubMed Central  Google Scholar 

Appay R, Dehais C, Maurage CA et al (2019) CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas. Neuro Oncol 21:1519–1528

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wijnenga MMJ, French PJ, Dubbink HJ et al (2018) The impact of surgery in molecularly defined low-grade glioma: an integrated clinical, radiological, and molecular analysis. Neuro Oncol 20:103–112

Article  CAS  PubMed  Google Scholar 

Patel SH, Bansal AG, Young EB et al (2019) Extent of surgical resection in lower-grade gliomas: differential impact based on molecular subtype. AJNR Am J Neuroradiol 40:1149–1155

Article  CAS  PubMed  PubMed Central  Google Scholar 

Weller M, van den Bent M, Preusser M et al (2021) EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol 18:170–186

Article  PubMed  Google Scholar 

Suzuki H, Aoki K, Chiba K et al (2015) Mutational landscape and clonal architecture in grade II and III gliomas. Nat Genet 47:458–468

Article  CAS  PubMed  Google Scholar 

Cairncross G, Wang M, Shaw E et al (2013) Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol: Off J Am Soc Clin Oncol 31:337–343

Article  CAS  Google Scholar 

van den Bent MJ, Brandes AA, Taphoorn MJ et al (2013) Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol: Off J Am Soc Clin Oncol 31:344–350

Article  Google Scholar 

Buckner JC, Shaw EG, Pugh SL et al (2016) Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma. N Engl J Med 374:1344–1355

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bell EH, Zhang P, Shaw EG et al (2020) Comprehensive genomic analysis in NRG oncology/RTOG 9802: a phase III trial of radiation versus radiation plus procarbazine, lomustine (CCNU), and vincristine in high-risk low-grade glioma. J Clin Oncol: Off J Am Soc Clin Oncol 38:3407–3417

Article  CAS  Google Scholar 

National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Central Nervous System Tumours. (2023) https://www.nccn.org. Accessed 10 Jan 2024

van den Bent MJ (2014) Practice changing mature results of RTOG study 9802: another positive PCV trial makes adjuvant chemotherapy part of standard of care in low-grade glioma. Neuro Oncol 16:1570–1574

Article  PubMed  PubMed Central  Google Scholar 

Jaeckle KA, Ballman KV, van den Bent M et al (2021) CODEL: phase III study of RT, RT + TMZ, or TMZ for newly diagnosed 1p/19q codeleted oligodendroglioma. Analysis from the initial study design. Neuro Oncol 23:457–467

Article  PubMed  Google Scholar 

Wick W, Roth P, Hartmann C et al (2016) Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide. Neuro Oncol 18:1529–1537

CAS  PubMed  PubMed Central  Google Scholar 

Taal W, van der Rijt CC, Dinjens WN et al (2015) Treatment of large low-grade oligodendroglial tumors with upfront procarbazine, lomustine, and vincristine chemotherapy with long follow-up: a retrospective cohort study with growth kinetics. J Neurooncol 121:365–372

Article  CAS  PubMed  Google Scholar 

Baumert BG, Hegi ME, van den Bent MJ et al (2016) Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033–26033): a randomised, open-label, phase 3 intergroup study. Lancet Oncol 17:1521–1532

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wick W, Hartmann C, Engel C et al (2009) NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol 27:5874–5880

Article  CAS  PubMed  Google Scholar 

Johnson BE, Mazor T, Hong C et al (2014) Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science (New York, NY) 343:189–193

Article  CAS  Google Scholar 

Sasaki H, Hirose Y, Yazaki T et al (2015) Upfront chemotherapy and subsequent resection for molecularly defined gliomas. J Neurooncol 124:127–135

Article  CAS  PubMed  Google Scholar 

Hata N, Yoshimoto K, Hatae R et al (2016) Deferred radiotherapy and upfront procarbazine-ACNU-vincristine administration for 1p19q codeleted oligodendroglial tumors are associated with favorable outcome without compromising patient performance, regardless of WHO grade. Onco Targets Ther 9:7123–7131

Article  CAS  PubMed  PubMed Central  Google Scholar 

Iwadate Y, Matsutani T, Hara A et al (2019) Eighty percent survival rate at 15 years for 1p/19q co-deleted oligodendroglioma treated with upfront chemotherapy irrespective of tumor grade. J Neurooncol 141:205–211

Article  CAS  PubMed  Google Scholar 

Wolff JE, Berrak S, Koontz Webb SE, Zhang M (2008) Nitrosourea efficacy in high-grade glioma: a survival gain analysis summarizing 504 cohorts with 24193 patients. J Neurooncol 88:57–63

Article  PubMed  Google Scholar 

Kanazawa T, Fujiwara H, Takahashi H et al (2019) Imaging scoring systems for preoperative molecular diagnoses of lower-grade gliomas. Neurosurg Rev 42:433–441

Article  PubMed  Google Scholar 

Patel SH, Poisson LM, Brat DJ et al (2017) T2-FLAIR mismatch, an imaging biomarker for IDH and 1p/19q status in lower-grade gliomas: a TCGA/TCIA project. Clin Cancer Res: Off J American Assoc Cancer Res 23:6078–6085

Article  CAS  Google Scholar 

Kanazawa T, Ohara K, Kitamura Y et al (2021) Histopathological investigation of the 1p/19q-codeleted gliomas resected following alkylating agent chemotherapy. J Neurooncol 155:235–246

Article  CAS  PubMed  Google Scholar